80 results
Page 4 of 4
8-K
EX-99.2
1b1vaxzagai 3546y
7 Jan 19
Regulation FD Disclosure
7:30am
8-K
EX-99.1
s36tv9kdoeu 5p195
20 Nov 18
Sage Therapeutics Receives Notification of PDUFA Extension
4:06pm
8-K
EX-99.1
eydq 4iq4wntn3bpp
6 Nov 18
Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
z7nhkxcd848xbj c10d2
2 Nov 18
Other Events
5:26pm
8-K
EX-99.1
j60mo
12 Jun 18
Sage Announces Pivotal Phase 3 Trial Status forSAGE-217 in Major Depressive Disorder and Postpartum
7:30am
8-K
EX-99.1
3dn10
30 May 18
Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression
7:30am
8-K
EX-99.1
eibhq j9awji79
13 Jul 16
Sage Reports Positive Top-line Results Including Demonstration of 30-Day Durability from
12:00am
10-K
ryqzn
6 Mar 15
Annual report
12:00am